Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgentex Group. Regulatory News (AGFX)

  • This share is currently suspended. It was suspended at a price of 2.45
  • There is currently no data for AGFX

Form 8 (DD) - Argentex Group PLC

20 Jun 2025 11:13

RNS Number : 7906N
IFX (UK) Ltd
20 June 2025
 

FORM 8 (DD)

 

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

IFX (UK) Limited (trading as IFX Payments)

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Argentex Group PLC

(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Offeror

(e) Date dealing undertaken:

19 June 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security:

 

Ordinary shares of £0.0001 each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,360,000

1.12%

NIL

NIL

(2) Cash-settled derivatives:

 

NIL

NIL

NIL

NIL

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

NIL

NIL

NIL

NIL

 

TOTAL:

1,360,000

1.12%

NIL

NIL

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary shares of £0.0001 each

Purchase

 

550,000

£0.024495

Ordinary shares of £0.0001 each

Purchase

610,000

£0.024495

Ordinary shares of £0.0001 each

Purchase

200,000

£0.0244

 

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

20 June 2025

Contact name:

Anastasia Evans

Telephone number:

+44 (0)20 7495 8888

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DCCFLFIIRRIIFIE
Date   Source Headline
26th Feb 20212:58 pmRNSDirector/PDMR Shareholding
17th Feb 20213:12 pmRNSHolding(s) in Company
9th Feb 20212:34 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSTrading update and Board changes
20th Nov 20207:00 amRNSInterim Results
19th Nov 20204:53 pmRNSHolding(s) in Company
4th Nov 20207:00 amRNSNotice of interim results
12th Oct 20207:00 amRNSDirector Declaration
12th Oct 20207:00 amRNSTrading Statement
6th Oct 20204:40 pmRNSSecond Price Monitoring Extn
6th Oct 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20204:40 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
21st Sep 20205:50 pmRNSChange of Registered Office
11th Sep 20202:18 pmRNSAGM Statement
7th Sep 20204:36 pmRNSPrice Monitoring Extension
10th Aug 20207:17 amRNSAnnual Report and Notice of Annual General Meeting
3rd Aug 20207:00 amRNSFull year results for period ending 31 March 2020
29th Jul 20204:35 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSNotice of Full Year Results
8th Jul 20205:24 pmRNSHolding(s) in Company
29th Jun 20209:11 amRNSHolding(s) in Company
27th May 20207:00 amRNSArgentex Group announces new headquarters
26th May 20204:40 pmRNSSecond Price Monitoring Extn
26th May 20204:35 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:40 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSTrading Update
27th Mar 20204:41 pmRNSSecond Price Monitoring Extn
27th Mar 20204:36 pmRNSPrice Monitoring Extension
25th Mar 20204:00 pmRNSDirector/PDMR Shareholding
18th Mar 202011:46 amRNSDirector/PDMR Shareholding
17th Mar 20204:43 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20204:41 pmRNSDirector/PDMR Shareholding
11th Mar 20204:41 pmRNSHolding(s) in Company
11th Mar 20204:41 pmRNSSecond Price Monitoring Extn
11th Mar 20204:35 pmRNSPrice Monitoring Extension
9th Mar 20204:41 pmRNSSecond Price Monitoring Extn
9th Mar 20204:37 pmRNSPrice Monitoring Extension
27th Feb 202012:07 pmRNSSecond Price Monitoring Extn
27th Feb 202012:02 pmRNSPrice Monitoring Extension
26th Feb 202012:08 pmRNSSecond Price Monitoring Extn
26th Feb 202012:02 pmRNSPrice Monitoring Extension
24th Feb 20204:40 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20197:00 amRNSInterim Results Statement
7th Oct 20197:00 amRNSTrading Update
5th Aug 20197:00 amRNSAppointment of Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.